Last reviewed · How we verify

ABT-SLV187 — Competitive Intelligence Brief

ABT-SLV187 (ABT-SLV187) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Soluble epoxide hydrolase (sEH) inhibitor. Area: Cardiovascular.

phase 3 Soluble epoxide hydrolase (sEH) inhibitor Soluble epoxide hydrolase (sEH) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ABT-SLV187 (ABT-SLV187) — AbbVie. ABT-SLV187 is a selective inhibitor of soluble epoxide hydrolase (sEH) that increases levels of epoxyeicosatrienoic acids (EETs) to reduce inflammation and improve cardiovascular function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABT-SLV187 TARGET ABT-SLV187 AbbVie phase 3 Soluble epoxide hydrolase (sEH) inhibitor Soluble epoxide hydrolase (sEH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Soluble epoxide hydrolase (sEH) inhibitor class)

  1. AbbVie · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-SLV187 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-slv187. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: